Divalproex Sodium FDA Label
Divalproex sodium, marketed under the brand name Depacon among others, is a medication primarily used to treat epilepsy and bipolar disorder. It's available in various dosage forms, including oral tablets and extended-release tablets. Understanding the details of divalproex sodium, as outlined in its FDA-approved label, is crucial for patients and healthcare providers to ensure safe and effective use.
This article delves into the critical aspects of divalproex sodium, as per the FDA label, focusing on its indications, dosage, side effects, warnings, and more. By exploring these key areas, we aim to provide a comprehensive, SEO-optimized guide that enhances understanding and fosters informed decision-making.
Indications and Usage
The FDA label specifies divalproex sodium's approved indications. It is primarily indicated for the:
- Prevention and treatment of absence seizures (a type of epilepsy) alone or in combination with other medications.
- Treatment of manic episodes associated with bipolar disorder, either as a monotherapy or as an adjunctive therapy to other medications.
- Prevention of migraines in adults.
These indications highlight the broad application of divalproex sodium, demonstrating its versatility in managing different neurological conditions.
Dosage and Administration
Divalproex sodium's dosage varies depending on the indication, age, and clinical response. The general starting dose for adults is 250mg to 1500mg daily, divided into two or three doses. For children, the starting dose is typically 15 to 30 mg/kg/day, also divided into two to three doses. The FDA label emphasizes the importance of dose optimization to minimize side effects and maximize therapeutic benefits.
Additionally, the labelprovides dosage adjustments for renal and hepatic impairment, ensuring safe use in patients with these comorbidities.
Warnings and Precautions
The FDA label lists several warnings and precautions for divalproex sodium, including:
- Hepatotoxicity (liver damage), which can occur at doses within the therapeutic range. Regular liver function tests are recommended while taking this medication.
- Pancreatitis, a serious inflammation of the pancreas that can be life-threatening.
- Teratogenicity, as divalproex sodium is known to cause malformations in a developing fetus if used during pregnancy. It is contraindicated in women of childbearing potential unless other medications prove ineffective or poorly tolerated.
- Suicidal thoughts and behaviors, particularly in patients with bipolar disorder, depression, or other psychiatric conditions. Close monitoring is crucial, especially during the initial stages of treatment.
Healthcare providers should thoroughly inform patients about these potential risks and monitor them closely during treatment.
Adverse Reactions
The FDA label also details the known adverse reactions of divalproex sodium, with the most common (incidence >10%) being:
- Nausea, vomiting, and stomach upset.
- Weight changes, including weight loss and weight gain.
- Dizziness and drowsiness.
- Double vision, blurred vision, and eye dryness.
- Headache, tremors, and hyperhidrosis (excessive sweating).
These adverse reactions, though common, may not require discontinuation of the medication, as they often improve over time or with dose adjustments.
Divalproex sodium's FDA label provides invaluable insight into the medication's safe and effective use. By adhering to the FDA guidelines, healthcare providers can strive to minimize risks and maximize therapeutic outcomes. Always consult the FDA label for the most accurate, up-to-date information.